BiologicalDrug
Tasadenoturev clinical trials
Also written DNX-2401 and Delta-24.
Keep track of what changes. Save the tasadenoturev studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 5
Clinica Universidad de Navarra, Universidad de Navarra (2) · DNAtrix, Inc. (1) · University of Alabama at Birmingham (1) · M.D. Anderson Cancer Center (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tasadenoturev is read from its arms, and is right about nine times in ten.
Testing it · 6
- Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingPhase 2University of California, San FranciscoNCT05009992Written as DNX-2401
- Intratumoral DNX-2401 for High Grade Pediatric Brain TumorsRecruitingPhase 2Clinica Universidad de Navarra, Universidad de NavarraNCT07424092Written as DNX-2401
- Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial MetastasesNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07444606Written as DNX-2401
- Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine GliomasCompletedPhase 1Clinica Universidad de Navarra, Universidad de NavarraNCT03178032Written as DNX-2401
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedPhase 2DNAtrix, Inc.NCT02798406Written as DNX-2401
- Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer PatientsCompletedPhase 1University of Alabama at BirminghamNCT00562003Written as Ad5-delta24RGD
Given in every arm · 2 — tasadenoturev is usual care beside what is tested
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT03896568Written as Oncolytic Adenovirus Ad5-DNX-2401
- DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant GliomasCompletedPhase 1DNAtrix, Inc.NCT00805376Written as DNX-2401
Codes
What other systems call tasadenoturev · ClinicalTrials.gg INT015437
- UNII (FDA) 79ME7DT193TASADENOTUREVOne source FDA
- NCI Thesaurus C74067TasadenoturevOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 79ME7DT193 | TASADENOTUREV | One source FDA |
| NCI Thesaurus | C74067 | Tasadenoturev | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.